| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 569.56 | 13.7% |
| Total Income | 569.56 | 13.7% |
| Expenditure | 474.01 | 12.7% |
| PBT | 69.61 | 29.1% |
| Net Profit | 50.49 | 29.8% |
| OPM | 16.79% | 0.75pp |
| NPM | 8.86% | 1.09pp |
| EPS | 0.39 | 30.0% |
Concentra Reports Q1 2026 Revenue Up 13.7% to $569.6 Million
08 May 2026 · 8 May, 2:27 am
Summary
Concentra Group Holdings Parent, Inc. reported a strong start to 2026, with Q1 revenue increasing by 13.7% to $569.6 million and net income rising by 28.7% to $52.3 million. Adjusted EBITDA also saw a significant increase of 17.6%, reaching $120.7 million. The company's performance was driven by growth in visit volumes and revenue per visit. Building on these results, Concentra raised its full-year 2026 guidance for revenue and Adjusted EBITDA. The Board of Directors declared a cash dividend of $0.0625 per share.
Key Highlights
- 1
Concentra's revenue for Q1 2026 reached $569.6 million, a 13.7% increase from $500.8 million in Q1 2025.
- 2
Net income for Q1 2026 was $52.3 million, up 28.7% from $40.6 million in Q1 2025.
- 3
Adjusted EBITDA for Q1 2026 increased by 17.6% to $120.7 million from $102.7 million in Q1 2025.
- 4
Earnings per share for Q1 2026 rose to $0.39, an increase of $0.09 over the prior year.
- 5
Patient visits in Q1 2026 totaled 3,419,091, an increase of 6.7% from Q1 2025.
- 6
The company raised its full-year 2026 revenue guidance to a range of $2.275 billion to $2.375 billion.
- 7
Concentra's Board of Directors declared a cash dividend of $0.0625 per share.
Management Comments
Keith Newton
Our strong start to 2026 is a testament to the trust our clients place in us to care for their most valuable asset: their people. The meaningful growth in visit volumes we saw this quarter demonstrates that our clinical model and value proposition continue to lead in workers' compensation. Building on our exceptional operational and financial performance, we remain focused on achieving key strategic objectives and positioning Concentra to deliver long-term shareholder value.
Matt DiCanio
Our Q1 results demonstrate the inherent strength of our operating model, with broad-based growth across our business supporting our decision to raise our full-year guidance. Beyond the balance sheet, we are focused on disciplined execution of our de novo pipeline and are on track to complete our transition from Select Medical Corporation in the coming months. As an independent company, we are optimizing our operational platform and infrastructure to drive sustained excellence and capitalize on our unique position as a leading health partner for the American workforce.”
Informational and educational content only. Not investment advice.